Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence.

Cureus · 2025 · PMC12450064 · PMID 40978864

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

For all-cause mortality, both DAPA-HF and the EMPEROR trials demonstrated a favorable trend, although reductions were not statistically significant in all subgroups, including non-diabetic patients [ 9 - 11 ].

also in 957 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.